View in EDS HTML Full Text PDF Full Text

Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects.

Saved in:
Bibliographic Details
Title: Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects.
Authors: Zhang, Meng-Jie1,2 (AUTHOR), Chen, Yirong1 (AUTHOR), Zhang, Caixia1 (AUTHOR), Bian, Xiaofeng3 (AUTHOR), Zhang, Xiangyang4 (AUTHOR), Huang, Shijia1 (AUTHOR), Yang, Bowen1 (AUTHOR), Lu, Siyan1 (AUTHOR), Fu, Xueting3 (AUTHOR), Zhao, Wei5 (AUTHOR) zhaowei_njmu@163.com, Kong, Xu-Dong2 (AUTHOR) xudong.kong@sjtu.edu.cn, Zhao, Shuli1,3 (AUTHOR) shulizhao79@njmu.edu.cn
Source: Cellular Oncology (2211-3428). Dec2025, Vol. 48 Issue 6, p1757-1774. 18p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:22113428
DOI:10.1007/s13402-025-01105-1